Recap: Biomerica Q1 Earnings
Biomerica(NASDAQ:BMRA) stock rose by 2.53% on Monday after the company reported its Q1 earnings results on Friday, October 15, 2021 at 06:30 AM.
Here's what investors need to know about the announcement.
Biomerica Tweets ‘BUY NOW!’ Referencing Colon Disease Test Being Sold At Walmart
https://twitter.com/biomerica_inc/status/1449059366846533637
The Daily Biotech Pulse: Moderna’s Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Biomerica Q1 EPS $(0.12), Inline, Sales $1.26M Miss $2.05M Estimate
Biomerica (NASDAQ:BMRA) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period last year. The
5 Short Squeeze Candidates To Watch: Bit Digital, Camber Energy Rejoin The List
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp. (NYSE: GME) and AMC Entertainment Holdings Inc (NYSE: AMC), two stocks that attracted strong interest and saw
44 Biggest Movers From Yesterday
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.
30 Stocks Moving In Monday’s Mid-Day Session
Gainers
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints.